Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference
SAN DIEGO , June 15, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 21 , at 1:30 p.m. EDT .
View HTML
Toggle Summary Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO , June 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017 , stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
SAN DIEGO , June 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors.  Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry. 
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th
SAN DIEGO , June 1, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT . The conference will take place June
View HTML
Toggle Summary Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present
View HTML
Toggle Summary Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
SAN DIEGO , May 16, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH),
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
- Clinical Data from Multiple Phase 2 Development Programs Expected in 2017 -<br>- Ralinepag Phase 2 Study Results Expected in July -
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017
SAN DIEGO , May 2, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that the Company will release its first quarter 2017 financial results and provide a
View HTML
Toggle Summary Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , April 21, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock, offered at a price to the public of $1.15 per share.  The gross proceeds from the offering are expected to
View HTML